2415314
Project Grant
Overview
Grant Description
SBIR Phase I: Massive, empirical, scalable generation of small molecule and protein interaction data to enable the discovery of medicines at scale with machine learning.
The broader impact of this Small Business Innovation Research (SBIR) Phase I project will be to enable the discovery of new medicines at an unprecedented rate, by empowering researchers across the globe to launch discovery programs in weeks at a dramatically reduced entry price.
This is in contrast to the status quo of launching a drug discovery program, which costs hundreds of thousands of dollars, requires expensive company resources, and several months of time prior to an initial readout on progress.
The outcome of this new ability may be an increased number of therapeutics that are able to make it through clinical trials and ultimately to patients.
The innovation could provide data of interactions between billions of unique small molecules and the entire human proteome.
This could enable the creation of sophisticated and predictive machine learning based models to predict novel interactions between small molecules and protein sequences.
The validation and expansion of this approach would allow for continuous improvement of the ability to predict new medicines for emerging diseases.
The proposed project will seek to demonstrate the ability to encapsulate proteins and small molecules in millions of molecular barcoded pico-scale compartments and identify the specific interactions between the proteins and small molecules contained within each of them.
The intellectual merit of the activity is in the construction of the materials and methods that enable this capability, which reduces the cost of a single protein and small molecule library screen by over 100X.
Current methodologies are limited to screening in much larger formats, leading to higher costs, limited parallelization, and large quantities of material required for the screen to be used.
In contrast, the innovation herein could allow for a dramatic reduction in the amount of materials required, enabling the screening of proteins in high parallelization through miniaturization, and consequently reducing cost and time required to generate a comparable sized dataset by orders of magnitude.
The project goals will be to (1) determine with control systems the ability to identify known interactions in the pico-scale format, (2) determine if non-control protein interactions are able to be identified in at 10-plex format, (3) and to determine if protein selective molecules are able to be identified in a single screen.
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the foundation's intellectual merit and broader impacts review criteria.
Subawards are not planned for this award.
The broader impact of this Small Business Innovation Research (SBIR) Phase I project will be to enable the discovery of new medicines at an unprecedented rate, by empowering researchers across the globe to launch discovery programs in weeks at a dramatically reduced entry price.
This is in contrast to the status quo of launching a drug discovery program, which costs hundreds of thousands of dollars, requires expensive company resources, and several months of time prior to an initial readout on progress.
The outcome of this new ability may be an increased number of therapeutics that are able to make it through clinical trials and ultimately to patients.
The innovation could provide data of interactions between billions of unique small molecules and the entire human proteome.
This could enable the creation of sophisticated and predictive machine learning based models to predict novel interactions between small molecules and protein sequences.
The validation and expansion of this approach would allow for continuous improvement of the ability to predict new medicines for emerging diseases.
The proposed project will seek to demonstrate the ability to encapsulate proteins and small molecules in millions of molecular barcoded pico-scale compartments and identify the specific interactions between the proteins and small molecules contained within each of them.
The intellectual merit of the activity is in the construction of the materials and methods that enable this capability, which reduces the cost of a single protein and small molecule library screen by over 100X.
Current methodologies are limited to screening in much larger formats, leading to higher costs, limited parallelization, and large quantities of material required for the screen to be used.
In contrast, the innovation herein could allow for a dramatic reduction in the amount of materials required, enabling the screening of proteins in high parallelization through miniaturization, and consequently reducing cost and time required to generate a comparable sized dataset by orders of magnitude.
The project goals will be to (1) determine with control systems the ability to identify known interactions in the pico-scale format, (2) determine if non-control protein interactions are able to be identified in at 10-plex format, (3) and to determine if protein selective molecules are able to be identified in a single screen.
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the foundation's intellectual merit and broader impacts review criteria.
Subawards are not planned for this award.
Awardee
Funding Goals
THE GOAL OF THIS FUNDING OPPORTUNITY, "NSF SMALL BUSINESS INNOVATION RESEARCH (SBIR)/ SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAMS PHASE I", IS IDENTIFIED IN THE LINK: HTTPS://WWW.NSF.GOV/PUBLICATIONS/PUB_SUMM.JSP?ODS_KEY=NSF23515
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
La Jolla,
California
92037-1376
United States
Geographic Scope
Single Zip Code
OM Therapeutics was awarded
Project Grant 2415314
worth $275,000
from National Science Foundation in December 2024 with work to be completed primarily in La Jolla California United States.
The grant
has a duration of 5 months and
was awarded through assistance program 47.084 NSF Technology, Innovation, and Partnerships.
The Project Grant was awarded through grant opportunity NSF Small Business Innovation Research / Small Business Technology Transfer Phase I Programs.
SBIR Details
Research Type
SBIR Phase I
Title
SBIR Phase I: Massive, empirical, scalable generation of small molecule and protein interaction data to enable the discovery of medicines at scale with machine learning
Abstract
The broader impact of this Small Business Innovation Research (SBIR) Phase I project will be to enable the discovery of new medicines at an unprecedented rate, by empowering researchers across the globe to launch discovery programs in weeks at a dramatically reduced entry price. This is in contrast to the status quo of launching a drug discovery program, which costs hundreds of thousands of dollars, requires expensive company resources, and several months of time prior to an initial readout on progress. The outcome of this new ability may be an increased number of therapeutics that are able to make it through clinical trials and ultimately to patients. The innovation could provide data of interactions between billions of unique small molecules and the entire human proteome. This could enable the creation of sophisticated and predictive machine learning based models to predict novel interactions between small molecules and protein sequences. The validation and expansion of this approach would allow for continuous improvement of the ability to predict new medicines for emerging diseases.
The proposed project will seek to demonstrate the ability to encapsulate proteins and small molecules in millions of molecular barcoded pico-scale compartments and identify the specific interactions between the proteins and small molecules contained within each of them. The Intellectual Merit of the activity is in the construction of the materials and methods that enable this capability, which reduces the cost of a single protein and small molecule library screen by over 100X. Current methodologies are limited to screening in much larger formats, leading to higher costs, limited parallelization, and large quantities of material required for the screen to be used. In contrast, the innovation herein could allow for a dramatic reduction in the amount of materials required, enabling the screening of proteins in high parallelization through miniaturization, and consequently reduc
Topic Code
BT
Solicitation Number
NSF 23-515
Status
(Complete)
Last Modified 12/3/24
Period of Performance
12/1/24
Start Date
5/31/25
End Date
Funding Split
$275.0K
Federal Obligation
$0.0
Non-Federal Obligation
$275.0K
Total Obligated
Activity Timeline
Additional Detail
Award ID FAIN
2415314
SAI Number
None
Award ID URI
SAI EXEMPT
Awardee Classifications
Small Business
Awarding Office
491503 TRANSLATIONAL IMPACTS
Funding Office
491503 TRANSLATIONAL IMPACTS
Awardee UEI
TQ96UNTTHYR6
Awardee CAGE
None
Performance District
CA-50
Senators
Dianne Feinstein
Alejandro Padilla
Alejandro Padilla
Modified: 12/3/24